Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy

Shandiz Shahbazi; Cody J. Peer; William D. Figg

doi:10.4161/cbt.29504

Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy

Shandiz Shahbazi, Cody J. Peer, William D. Figg^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

4 Scopus citations

Original language	English
Pages (from-to)	1117-1119
Number of pages	3
Journal	Cancer Biology and Therapy
Volume	15
Issue number	9
DOIs	https://doi.org/10.4161/cbt.29504
State	Published - Sep 2014
Externally published	Yes

Keywords

Burkitt lymphoma
Epoch regimen
Low-intensity therapy

Access to Document

10.4161/cbt.29504

Cite this

@article{228662cfa6b54f6cbfa15f1a209453a3,

title = "Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy",

keywords = "Burkitt lymphoma, Epoch regimen, Low-intensity therapy",

author = "Shandiz Shahbazi and Peer, {Cody J.} and Figg, {William D.}",

year = "2014",

month = sep,

doi = "10.4161/cbt.29504",

language = "English",

volume = "15",

pages = "1117--1119",

journal = "Cancer Biology and Therapy",

issn = "1538-4047",

number = "9",

}

TY - JOUR

T1 - Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy

AU - Shahbazi, Shandiz

AU - Peer, Cody J.

AU - Figg, William D.

PY - 2014/9

Y1 - 2014/9

KW - Burkitt lymphoma

KW - Epoch regimen

KW - Low-intensity therapy

UR - http://www.scopus.com/inward/record.url?scp=84906826044&partnerID=8YFLogxK

U2 - 10.4161/cbt.29504

DO - 10.4161/cbt.29504

M3 - Comment/debate

C2 - 24919059

AN - SCOPUS:84906826044

SN - 1538-4047

VL - 15

SP - 1117

EP - 1119

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

IS - 9

ER -

Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy

Keywords

Access to Document

Fingerprint

Cite this